Tagged with CUHK

Hong Kong Insighta, formed this year as a 50/50 joint venture between genomics-focused outfit Prenetics and one of the city’s most feted scientific sons, Professor Dennis Lo, is aiming to change the face of cancer care via widespread early detection.   While early detection is widely recognised as crucial to enhancing cancer…

Hong Kong One of Asia’s most pre-eminent oncologists, Professor Tony Mok is perhaps best known for discovering the EGFR mutation gene and subsequently developing a targeted therapy that is more precise and personalized than standard chemotherapy. Here, Professor Mok discusses his current research areas of focus, some of the key clinical trial…

Hong Kong A groundbreaking research scientist noted for his work in non-invasive blood-based diagnoses, Professor Dennis Lo currently holds a number of positions at the Chinese University of Hong Kong (CUHK). Lo, whose work was first commercialised via the company Cirina – later acquired by GRAIL – outlines his current research focus on…

Hong Kong With the global market for cell and gene therapy (CGT) products set to skyrocket in the coming years, Hong Kong is looking to get in on the action with the opening of a new Advanced Therapy Products (ATP) Good Manufacturing Practice (GMP) Centre earlier this month.   Leveraging the city’s…

Hong Kong Prof. Michael Yang, an accomplished scientist and start-up expert, introduces the goals of the fast-growing Biomedical Sciences Department of City University Hong Kong. He unveils the contribution of Hong Kong to the Greater Bay Area in the biomedical field, while analyzing the key elements to change so the region can…

Hong Kong Professor Justin Wu, chief operating officer of the Chinese University of Hong Kong (CUHK) Medical Center, shares his professional background and interest in gastroenterology, his insights into the research and commercialization environment in Hong Kong, and his hope for government, industry and academia to work together to propel Hong Kong…

Hong Kong Small markets must inevitably etch out a niche positioning for themselves, and for Hong Kong, its world-class medical infrastructure, world-renowned academics and clinicians as well as high population density make it a strong contender in clinical research.   Hong Kong is an important piece of our global R&D landscape Scott…

Hong Kong Described as the first unicorn [a startup company valued at over USD 1 billion] of Hong Kong, Cirina has recently merged with Grail to further improve detection of cancer at its early stage. Pharmaboardroom sat down with Professor Denis Lo, the man behind Cirina’s technology, to further discuss his groundbreaking…